The state of the hunt:Pfizer and BioNTech plan to seek authorization of their vaccine for adolescents age 12-15 after promising Phase 3 results.
J&J agreed to supply up to 400 million doses of Janssen’s jab to the African Union.
Serum Institute of India launched clinical trials of its version of the Novavax vaccine candidate.
Approved or authorized vaccines
New data show lower efficacy for Pfizer/BioNTech: The…